lifestyle.luxedb.com

Author: Generate:Biomedicines

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

February 26, 2026
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

December 1, 2025